HDAC inhibitors comprise structurally diverse compounds that are used as targeted anticancer agents, since Class I HDACs, such as HDAC1 and HDAC3, are overexpressed in various cancers and are associated with cellular proliferation [16,17,18,19]. Here, HDAC9 is linked to cancer.